Clinical Trials

trog-smallGenesis CancerCare and Trans-Tasman Radiation Oncology Group Strategic Partnership

The Trans-Tasman Radiation Oncology Group (TROG) is a global leader in radiotherapy research working with over nine hundred researchers and doctors in more than 50 trials involving over 12,000 patient volunteers to help advance cancer treatments. GenesisCare is the leading provider of radiation oncology in Australia undertaking around 320,000 cancer treatments every year and is currently involved in over 40 clinical trials. GenesisCare and TROG will work together to improve patient access to clinical trials and promote innovation in research to deliver better patient outcomes.

Clinical Trials 

Genesis Cancer Care Queensland is committed to the participation and co-ordination of clinical trials within its practices.

The table below details the clinical trials currently recruiting, and those in the follow-up phase. Please click the provided link to go to the public trial register which provides even further information on each of the respective trials.

Recruiting Trials (Patients are being enrolled)
***ANZMTG 01/07 (WBRTMel)

Trial Link
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial This international, randomized, phase III trial will determine if the addition of whole brain radiotherapy after surgery or local stereotactic radiotherapy improves the control of melanoma metastases in the brain, neurocognitive function, survival and quality of life.
ANZMTG 1-09/ TROG 08.09 (RTN2)

Trial Link
A randomised trial of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck This is a 2-armed randomised controlled trial comparing surgery alone with surgery plus post-operative radiation therapy for patients with completely resected primary melanoma showing histological features of neurotropism.

Trial Link
A randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD The study will compare the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or with currently available antiandrogen drugs for improving the survival in men with localised prostate cancer at high risk of recurrence.
Follow up trials (Recruitment completed, data collection on patients continues)
TROG 03.01

Trial Link
A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of dysphagia in patients treated with radiotherapy versus chemotherapy This study will compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy.
TROG 03.04 (RADAR)

Trial Link
A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will prevent bone loss caused by androgen deprivation therapy and further reduce relapse risk by impeding the development of bony metastases.
TROG 07.01 (DCIS)

Trial Link
A randomised Phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast This  trial addresses an urgent clinical need to provide information for an evidence-based practice in the individualised management of women with DCIS.
TROG 99.03 (NHLLOW5)

Trial Link
A randomised multicentre trial of involved field radiotherapy versus involved field radiotherapy plus chemotherapy in combination with Rituximab (MabThera®) for stage I-II low grade follicular lymphoma Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy plus chemotherapy). The main endpoint is progression free survival but overall survival and the influence of t(14;18) status will also be studied.
*TROG 08.03 (RAVES)

Trial Link
A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with surveillance and early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy RAVES will study whether it is best to defer radiotherapy until the PSA begins to rise (called salvage radiotherapy) or give immediate radiotherapy after surgery
TROG 08.06 (STARS)

Trial Link
A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy The purpose of this study is to determine whether starting anastrozole prior to radiotherapy, so that it is taken during radiotherapy, decreases local recurrence of breast cancer in post-menopausal women in comparison to waiting until after radiotherapy to commence anastrozole.
TROG 09.03 (MP3)

Trial Link
An efficacy study of Chemo-Radiotherapy in Positron Emission Tomography (PET) Merkel Cell Carcinoma of the Skin A Phase II Study designed to evaluate the efficacy of chemo-radiotherapy in achieving loco-regional control in patients with Merkel Cell Carcinoma (MCC) of the skin. Patients will undergo PET scans to assist in staging and planning the patient's treatment as well as assessing response at the conclusion of treatment.


  • * TROG = Trans Tasman Radiation Oncology Group
  • ** ANZMTG = Australia New Zealand Melanoma Trials Group
  • *** NCIC = National Cancer Institute of Canada Clinical Trials Group


If you are interested in being involved with any of the active (recruiting) trials please discuss with your radiation oncologist at the time of your consultation.


Follow us on Facebook

Genesis Logo Small.pngGenesisCare is Australia’s leading provider of radiation oncology, cardiology and sleep treatments. We exist to fill the treatment gap for the biggest disease burdens in Australia - cancer and cardiovascular disease - in an environment of substantial unmet demand from an ageing population. Click here to learn more